company background image
AXGN

AxoGenNasdaqCM:AXGN Stock Report

Market Cap

US$391.9m

7D

-3.1%

1Y

-36.3%

Updated

02 Dec, 2021

Data

Company Financials +
AXGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AXGN Stock Overview

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.

AxoGen Competitors

Stryker

NYSE:SYK

US$90.2b

Baxter International

NYSE:BAX

US$37.6b

Integra LifeSciences Holdings

NasdaqGS:IART

US$5.3b

Orthofix Medical

NasdaqGS:OFIX

US$607.0m

Price History & Performance

Summary of all time highs, changes and price drops for AxoGen
Historical stock prices
Current Share PriceUS$10.11
52 Week HighUS$23.94
52 Week LowUS$9.11
Beta0.70
1 Month Change-33.66%
3 Month Change-41.80%
1 Year Change-36.25%
3 Year Change-67.60%
5 Year Change21.08%
Change since IPO273.06%

Recent News & Updates

Aug 25

Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing

Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels. COVID-19 infections are definitely a short-term risk and an impediment to sales and training efforts, but usage among trained surgeons and core accounts continues to grow nicely. Data in 2022 and 2023 should accelerate adoption, helping smooth the path to 20% or better revenue growth with products that provide demonstrable clinical and quality of life benefits. Axogen shares look undervalued below the mid-$20s.

Aug 07
Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?

Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

AXGNUS Medical EquipmentUS Market
7D-3.1%-4.9%-4.9%
1Y-36.3%9.5%17.8%

Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 9.5% over the past year.

Return vs Market: AXGN underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is AXGN's price volatile compared to industry and market?
AXGN volatility
AXGN Average Weekly Movement8.4%
Medical Equipment Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.4%

Stable Share Price: AXGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AXGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a357Karen Zaderejhttps://www.axogeninc.com

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed.

AxoGen Fundamentals Summary

How do AxoGen's earnings and revenue compare to its market cap?
AXGN fundamental statistics
Market CapUS$391.93m
Earnings (TTM)-US$27.71m
Revenue (TTM)US$128.32m

3.3x

P/S Ratio

-15.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AXGN income statement (TTM)
RevenueUS$128.32m
Cost of RevenueUS$22.97m
Gross ProfitUS$105.35m
ExpensesUS$133.06m
Earnings-US$27.71m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin82.10%
Net Profit Margin-21.59%
Debt/Equity Ratio43.4%

How did AXGN perform over the long term?

See historical performance and comparison

Valuation

Is AxoGen undervalued compared to its fair value and its price relative to the market?

3.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXGN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AXGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXGN's PB Ratio (3.6x) is in line with the US Medical Equipment industry average.


Future Growth

How is AxoGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

29.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXGN's revenue (17.6% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AXGN's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has AxoGen performed over the past 5 years?

-15.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXGN is currently unprofitable.

Growing Profit Margin: AXGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXGN is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: AXGN has a negative Return on Equity (-24.04%), as it is currently unprofitable.


Financial Health

How is AxoGen's financial position?


Financial Position Analysis

Short Term Liabilities: AXGN's short term assets ($135.0M) exceed its short term liabilities ($23.4M).

Long Term Liabilities: AXGN's short term assets ($135.0M) exceed its long term liabilities ($71.3M).


Debt to Equity History and Analysis

Debt Level: AXGN has more cash than its total debt.

Reducing Debt: AXGN's debt to equity ratio has reduced from 1993% to 43.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXGN has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 20.1% each year.


Dividend

What is AxoGen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AXGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AXGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Karen Zaderej (59 yo)

10.25yrs

Tenure

US$4,051,482

Compensation

Ms. Karen Zaderej has been President and Chief Executive Officer of AxoGen, Inc. since September 30, 2011. She was the Director of Viveve Medical Inc. from September 13, 2018 until May 4, 2020. She has ser...


CEO Compensation Analysis

Compensation vs Market: Karen's total compensation ($USD4.05M) is above average for companies of similar size in the US market ($USD1.75M).

Compensation vs Earnings: Karen's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AXGN's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: AXGN's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

AxoGen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AxoGen, Inc.
  • Ticker: AXGN
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$391.935m
  • Shares outstanding: 41.56m
  • Website: https://www.axogeninc.com

Number of Employees


Location

  • AxoGen, Inc.
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua
  • Florida
  • 32615
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:40
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.